StageBio

Executive Summary

StageBio is a private contract research organization (CRO) specializing exclusively in preclinical histopathology, pathology, and specimen archiving services. Founded in 2016 and headquartered in Mount Jackson, Virginia, the company partners with biopharmaceutical and medical device developers to provide GLP-compliant support from discovery through regulatory submission. By focusing solely on pathology, StageBio differentiates itself from full-service CROs, offering deep expertise and regulatory-ready data that help de-risk client programs. Its services are critical for toxicology studies, biomarker analysis, and safety assessment, positioning the company as a key partner in the drug development value chain. The preclinical CRO market is growing steadily, driven by rising R&D spending and outsourcing trends. StageBio's specialization and GLP compliance make it well-positioned to capture demand from small and mid-sized biotechs seeking reliable pathology partners. While the company operates in a competitive landscape, its focused model and experienced team may drive expansion through capacity additions or strategic alliances. With no disclosed funding or valuation, StageBio appears to be bootstrapped or backed by private investors. Near-term growth will likely hinge on winning new contracts and potentially scaling its laboratory infrastructure.

Upcoming Catalysts (preview)

• Q3 2026Announcement of new histopathology laboratory expansion70% success
• Q4 2026Strategic partnership agreement with a top-20 biopharma company50% success
• Q2 2026GLP certification for additional service lines (e.g., digital pathology)80% success